Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

182 results about "Initial treatment" patented technology

First-line treatment or therapy simply refers to the initial, or first treatment recommended for a disease or illness. This may also be referred to as primary treatment, initial treatment, or induction therapy.

Mobile station and methods for diagnosing and modeling site specific full-scale effluent treatment facility requirements

A mobile station and methods are disclosed for diagnosing and modeling site specific effluent treatment facility requirements to arrive at a treatment regimen and/or proposed commercial plant model idealized for the particular water/site requirements. The station includes a mobile platform having power intake, effluent intake and fluid outflow facilities and first and second suites of selectably actuatable effluent pre-treatment apparatus. An effluent polishing treatment array is housed at the station and includes at least one of nanofiltration, reverse osmosis and ion-exchange stages. A suite of selectively actuatable post-treatment apparatus is housed at the station. Controls are connected at the station for process control, monitoring and data accumulation. A plurality of improved water treatment technologies is also disclosed. The modeling methods include steps for analyzing raw effluent to be treated, providing a field of raw effluent condition entry values and a field of treated effluent condition goals entry values, and utilizing said fields to determine an initial treatment model including a selection of, and use parameters for, treatment technologies from the plurality of down-scaled treatment technologies at the facility, the model dynamically and continuously modifiable during treatment modeling.
Owner:ROCKWATER RESOURCE

Method and system for improving vascular systems in humans using biofeedback and network data communication

Methods for treating vascular disease in humans and generating data representing treatment plans are disclosed. A first set of clinical vascular health data from a healthcare provider and representing a vascular health condition of a patient is received at a data center server that is communicatively coupled to a public data network. One or more vascular disease analysis algorithms are applied to the first set of vascular health data, to result in creating and storing an initial treatment plan for the patient. A second set of vascular health data is received from a monitoring device that is associated with the patient and that is communicatively coupled to the data network; the second set of data include Doppler monitor data obtained from the peripheral vascular system of the patient. One or more vascular analysis algorithms are applied to result in creating one or more supplementary treatment plans for the patient. At least one of the treatment plans includes a biofeedback interaction. The treatment plans are provided to the patient over the data network. The foregoing steps are iteratively repeated one or more times as determined by the physician and patient, resulting in improved vascular health.
Owner:ALEXANDER FRANCIS CASTELLANOS 2002 TRUST

Compositions and methods for affecting movement of contaminants, bodily fluids or other entities, and/or affecting other physiological conditions

Compositions which self-assemble under physiological conditions are formulated for application to wounds. The formulations include a pharmaceutically acceptable carrier or are provided as part of a medical device or coating. The formulations may also include other therapeutic, prophylactic or diagnostic agents. The formulation can be administered as appropriate for treatment of one or more disorders or conditions. For example, the formulation may be applied to repair an injury or during surgery of the lung, eye or dura, or following an epidural or spinal tap, to stop leakage of blood, interstitial fluid, or cerebrospinal fluid. The formulation may be administered to a burn or ulcer. The formulation may be dispersed in a suture or adhesive for administration at the time of or as released following suturing or gluing of a wound, thereby limiting bleeding, loss of tissue fluids, or other fluids such as those produced by parenchymal tissues such as the liver, pancreas, and gastrointestinal tract. The formulation may be applied to any site of bleeding, in a bandage, gauze, sponge, or other material, for immediate control of bleeding, or released later to control bleeding if the initial treatment such as suturing or pressure is insufficient. In one embodiment, the formulation is provided as a dry or lyophilized powder. In another embodiment, the material is provided in water. In another embodiment, the material is provided in combination with an oil and forms a laminate. In another embodiment, the formulation is provided as a coating on a device, for example a stent or a catheter. The material is also useful to isolate tissue, for preservation of tissue for subsequent transplantation or reattachment, and as a bulking, stabilizing or hydrating agent.
Owner:VERSITECH LTD +1

Intraoral mandibular advancement device for treatment of sleep disorders, including snoring, obstructive sleep apnea, and gastroesophageal reflux disease and method for delivering the same

An intraoral mandibular advancement device to treat problems associated with sleep disorders in a user having an obstructed airway, the disorders including, without limitation, snoring, obstructive sleep apnea, gastroesophageal reflux disease and / or bruxism having a main body for attachment to the user's mouth and having a central portion; a protrusive element distending from the central portion of the main body such that when worn by the user the element causes mandibular advancement sufficient to expand the oropharangeal space and reduce the obstruction; and a retainer extending from the main body for retention of the device in the user's mouth when worn during the user's sleep state. The main body is either complimentary with the user's palate and lingual surfaces of the maxillary teeth, rests against the palate and lingual surface of the user's anterior mandibular teeth when the device is inserted in the user's mouth, or customized to rest against two, four or six of the user's front teeth. The protrusive element is of distension between 5 and 15 mm, and optimally 10 mm downwardly from the main body, and can be adjusted such that the advancement ranges between 1.0 and 7.0 mm, and having an initial treatment protrusion of 3.0 to 4.0 mm, or ½ of the total potential maximum protrusive range. A method for diagnosis and delivery of the device is also shown.
Owner:LAMBERG STEVEN B

Mobile station and methods for diagnosing and modeling site specific full-scale effluent treatment facility requirements

A mobile station and methods are disclosed for diagnosing and modeling site specific effluent treatment facility requirements to arrive at a treatment regimen and / or proposed commercial plant model idealized for the particular water / site requirements. The station includes a mobile platform having power intake, effluent intake and fluid outflow facilities and first and second suites of selectably actuatable effluent pre-treatment apparatus. An effluent polishing treatment array is housed at the station and includes at least one of nanofiltration, reverse osmosis and ion-exchange stages. A suite of selectively actuatable post-treatment apparatus is housed at the station. Controls are connected at the station for process control, monitoring and data accumulation. A plurality of improved water treatment technologies is also disclosed. The modeling methods include steps for analyzing raw effluent to be treated, providing a field of raw effluent condition entry values and a field of treated effluent condition goals entry values, and utilizing said fields to determine an initial treatment model including a selection of, and use parameters for, treatment technologies from the plurality of down-scaled treatment technologies at the facility, the model dynamically and continuously modifiable during treatment modeling.
Owner:ROCKWATER RESOURCE

Lead-zinc smelting wastewater treatment method

The invention provides a lead-zinc smelting wastewater treatment method, which comprises the following steps: A, initial treatment of inflow; B, primary flocculation with an iron-based flocculating agent; C, secondary flocculation with polyacrylamide; D, filtration; E, adsorption with activated carbon; F, PH value regulation; G, membrane treatment: pumping water in a second regulation tank into a micro-filtration membrane device in a water pump pressurization form, pumping clear liquid filtered by the micro-filtration membrane device into a nanofiltration membrane device in the water pump pressurization form, pumping clear liquid filtered by the nanofiltration membrane device into a reverse osmosis device in the water pump pressurization form, and discharging or recycling clear liquid obtained by reverse osmosis of the reverse osmosis device after the clear liquid is detected to be qualified. According to the method, the iron-based flocculating agent and the polyacrylamide are adopted for performing flocculation twice, so that complete flocculation precipitation can be ensured; a filtration method combining micro-filtration, nanofiltration and reverse osmosis is adopted to deeply remove heavy metal ions such as lead and zinc ions in wastewater layer by layer, so that good removal effects are achieved.
Owner:SCI RES ACADEMY OF GUANGXI ENVIRONMENTAL PROTECTION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products